 "Dr Reddy's to market US-based PanTheryx's product DiaResQ in India")
Dr Reddy’s Laboratories Ltd has entered into a multi-country supply and licensing agreement with PanTheryx Inc, the US-based medical nutrition company, granting Dr Reddy’s the exclusive right to market and distribute PanTheryx’s nutritional intervention, DiaResQ, for infectious diarrhoea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. Dr Reddy’s will market the product in India and Nepal under the Reliqua brand.
G V Prasad, co-chairman and CEO, Dr Reddy’s, stated “This innovative product will address a significant unmet need in the area of diarrhoea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognised in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
“The opportunity to work with Dr Reddy’s to broadly introduce DiaResQ represents a significant milestone for our company. Dr Reddy’s is the recognised leader in the gastrointestinal market, and this agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products. This partnership further validates DiaResQ’s potential to improve the well-being and quality of life of millions of children and their families globally,” said Mark Braman, president and CEO of PanTheryx
Infectious diarrhoea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five. Almost 760,000 of these children under five die every year as a result of this condition. Paediatric infectious diarrhea kills nearly as many children as HIV/AIDS, malaria and measles combined, according to World Health Organization.
G V Prasad, co-chairman and CEO, Dr Reddy’s, stated “This innovative product will address a significant unmet need in the area of diarrhoea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognised in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
“The opportunity to work with Dr Reddy’s to broadly introduce DiaResQ represents a significant milestone for our company. Dr Reddy’s is the recognised leader in the gastrointestinal market, and this agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products. This partnership further validates DiaResQ’s potential to improve the well-being and quality of life of millions of children and their families globally,” said Mark Braman, president and CEO of PanTheryx
Infectious diarrhoea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five. Almost 760,000 of these children under five die every year as a result of this condition. Paediatric infectious diarrhea kills nearly as many children as HIV/AIDS, malaria and measles combined, according to World Health Organization.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%